About Us
-
We align with evolving global regulatory trends, including FDA initiatives, to support a shift toward reduced reliance on animal models.
-
We integrate micro-/nano-fabrication technologies with stem cell biology to engineer advanced, human-relevant tissue and organoid systems.
-
Our iPSC-derived organoid platforms enable disease modeling, drug evaluation, and translational regenerative medicine.
Our Team
代表取締役社長/CEO
Muxi Wang, PhD, received his doctoral degree from Kyoto University, previously served as a Specially Appointed Researcher at Kyoto University. He is currently the President of Toyo Industry Development Co., Ltd.. With a strong background in academic research and industrial development, he leads the company with a focus on technology-driven innovation, strategic business development, and the translation of advanced research into practical industrial applications.
取締役/CTO
Li Liu, MD, PhD, is a specially appointed Professor at the Graduate School of Engineering, Osaka University. Her research focuses on interdisciplinary approaches at the interface of medicine and engineering, with particular emphasis on cellular and tissue functional evaluation, biomedical imaging, and regenerative medicine technologies. She is dedicated to translating clinical needs into advanced engineering solutions for both fundamental research and translational applications.
取締役・技術専門家/Director of Technology
Junjun Li, PhD, is a specially appointed Associate Professor at the Graduate School of Engineering, Osaka University. His research focuses on the integration of micro-/nano-fabrication technologies with cell and tissue engineering, aiming to develop advanced platforms for cellular functional evaluation, disease modeling, and regenerative medicine. He is committed to bridging engineering innovation with biomedical and translational research.
Technology
-
Self-Sustained Traveling-Wave–Based Cardiac Maturation
We employ a self-generated traveling wave mechanism that does not require external pacing devices to functionally train immature iPSC-derived cardiomyocytes, promoting electrophysiological and mechanical maturation.
-
Dual Excitation–Contraction Recording System
We develop a dual excitation–contraction recording system that enables simultaneous measurement of electrical activity and contractile force in cardiomyocytes and engineered cardiac tissues, providing comprehensive electromechanical functional assessment.
-
Three-Dimensional Tissue Engineering
We design and fabricate 3D biomimetic scaffolds that support the construction of thick, structurally organized cellular tissues for tissue repair and regenerative applications.
-
High-Quality Regenerative Secretome Production
We utilize engineered three-dimensional tissues to produce high-quality conditioned media and secretomes, enabling scalable and cell-free approaches for regenerative medicine.
Company Profile
Company Name
EngiTissue Design Co., Ltd.
Date of Establishment
2024.12.26
Head Office
Techno Alliance Building C, 2-8 Yamadaoka, Suita, Osaka 565-0871 Japan
Laboratory
Room 319, Photonics Center (P3), 2-1 Yamadaoka, Suita, Osaka 565-0871 Japan
Business Activities
-
Design and manufacturing of iPSC-derived organoids
-
Development of 3D tissue platforms for disease modeling and drug screening
-
Cardiac tissue chips for cardiotoxicity and drug efficacy evaluation
-
Technical development and collaborative research support in regenerative medicine and tissue engineering
Main Clients
-
Universities and public research institutions
-
Pharmaceutical and biotechnology companies
-
Contract Research Organizations (CROs)
Representative
LIU Li, Ph.D, CTO
Capital
JPY 100 million